5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright

It has been a decent year for the biotech industry so far, buoyed by new drug approvals and positive regulatory/pipeline updates. The third-quarter earnings season has just kicked off, with most major biotech companies scheduled to report next week. The current momentum in the industry is mostly positive, with increasing R&D spending on lucrative areas such as obesity, gene-editing technologies and rare diseases.Companies in this volatile biotech industry continue to be in the spotlight as pharma/biotech go ...